| Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed WD Den Brok, CH Speers, L Gondara, E Baxter, SK Tyldesley, ... Breast cancer research and treatment 161, 549-556, 2017 | 174 | 2017 |
| Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the BC experience E Baxter, L Gondara, C Lohrisch, S Chia, K Gelmon, M Hayes, ... Current Oncology 22 (3), 192-198, 2015 | 17 | 2015 |
| Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience E Baxter, K Dennis, C Kollmannsberger, P Black, A Attwell, WJ Morris, ... Urologic Oncology: Seminars and Original Investigations 33 (2), 66. e13-66. e19, 2015 | 9 | 2015 |
| Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer EB Jackson, SKL Chia Journal of Clinical Oncology 41 (24), 3976-3983, 2023 | 4 | 2023 |
| Does age affect outcome with breast cancer? EB Jackson, L Gondara, C Speers, R Diocee, AM Nichol, C Lohrisch, ... The Breast, 2023 | 3 | 2023 |
| Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada EB Jackson, SJ Hotte Canadian Urological Association Journal 16 (11), E516, 2022 | 3 | 2022 |
| Current Challenges and Disparities in the Delivery of Equitable Breast Cancer Care in Canada EB Jackson, CE Simmons, SK Chia Current Oncology 30 (8), 7263-7274, 2023 | | 2023 |
| Abstract P4-03-15: Does age affect outcome? Data from a large cohort from British Columbia, 2005-2014 EB Jackson, L Gondara, CH Speers, K Gelmon Cancer Research 83 (5_Supplement), P4-03-15-P4-03-15, 2023 | | 2023 |
| Predicted financial impact of continued HER2-directed therapy in metastatic breast cancer: What is the financial toxicity in a public payer healthcare system? EB Jackson, L Corke, H Ohm, C Simmons CANCER RESEARCH 82 (4), 2022 | | 2022 |
| Abstract PD8-09: Predicted financial impact of continued HER2-directed therapy in metastatic breast cancer: What is the financial toxicity in a public payer healthcare system? EB Jackson, L Corke, H Ohm, C Simmons Cancer Research 82 (4_Supplement), PD8-09-PD8-09, 2022 | | 2022 |
| DESTINY-Breast01 Trial: trastuzumab deruxtecan in previously treated HER2 positive breast cancer EB Jackson, CE Simmons, KA Gelmon Translational Breast Cancer Research 2, 2021 | | 2021 |
| Outcomes of 3-weekly doxorubicin and cyclophosphamide followed by paclitaxel (AC/T) in a randomized trial (RCT) compared to a case-control matched British Columbia (BC) breast … SM Wilson, Y Zheng, JAW Chapman, MJ Burnell, C Speers, E Baxter, ... Journal of Clinical Oncology 32 (15_suppl), 1037-1037, 2014 | | 2014 |
